oops...last part didn't come across. Here it is
oops...last part didn't come across. Here it is again:
Here is my synopsis on te vaccines not approved by FDA but cleared for emergency use from small patient sampling’s from 40/60 thousand phase 3 trials, this is a hard ride awakening people.
We expect side effects from mRNA vaccines will become more prevalent over time and the weaknesses of mRNA vaccine technology will be exposed. Efficacy and side effect profiles observed in tightly controlled clinical trials often vary from real-world results, especially when trials are limited in scope and duration for accelerated EUA approval by a desperate FDA. In the case of COVID-19 mRNA vaccine trials, close examination of evidence suggests side effects observed in the clinical trials were downplayed or outright ignored. The best example of this is Bell’s Palsy.
In Pfizer’s trial 4 patients experienced “Bell’s Palsy” with 0 (zero) in the placebo group. In Moderna’s trial 3 patients experienced “Bell’s Palsy” with 1 in the placebo group. The FDA concluded that the “Bell’s Palsy” was not attributable to the vaccines because the event rates were similar to that seen in the general population. This logic is inconsistent with standard data interpretation and risk assessment because “Bell’s Palsy” occurred at a 400% higher rate in Pfizer’s trial and 300% higher rate in Moderna’s trial. Under normal circumstances this might have stopped the trials but under EUA it was ignored. But it gets worse... Bell’s Palsy by definition is temporary facial paralysis that completely resolves. Upon trial conclusion and FDA approval, 3 of the 4 cases in Pfizer’s trial were unresolved and 2 of the 3 cases in Moderna’s trial were unresolved (a combined 71.4% remained unresolved). The true and correct medical diagnosis at the time of FDA approval was facial paralysis. Only after paralysis resolves can it be diagnosed as Bell’s Palsy. It’s deceitful and negligent to label unresolved facial paralysis as Bell’s Palsy and was obviously done to downplay the risk and avoid reporting severe adverse events.
We suspect the facial paralysis could have been caused by non-neutralizing antibodies generated by the mRNA vaccines. Only a very small fraction of total antibodies generated from mRNA vaccines are neutralizing. The vast majority are non-neutralizing and pose a potential risk for harmful off-target binding, side effects, and autoimmunity. mRNA vaccines cannot predict or control antigen processing and presentation (i.e. how the Spike protein will be internalized by antigen processing cells, digested into peptides, processed and loaded onto MHC, and presented to the immune system for antibody production). This is a largely random process and peptides-antibodies can vary with each vaccine and booster and vary from person to person. With Generex’s Ii-Key-SARS-CoV-2 vaccine, we know exactly what peptides are being introduced. We know these peptides are being delivered in original pure form directly to MHC because Ii-Key bypasses the natural antigen processing system. Furthermore, using our computational vaccinology programs, we know our peptide sequences do not exist in the human body and harmful off-target antibody binding is not possible. We don’t use 1791 non neutralizing antibodies that Skew also very harmful Th2 from the very bad spike protein, we use only the best and safest parts, in addition these parts are in all variants and will not make our vaccine obsolete at all.
As far as being late to the vaccine race every single person who gets vaccinated by an MRNA vaccine that does not give longe term memory at all should take our vaccine because we will make them better and we can’t hurt you at all.
2
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Top 5 Most Recently Viewed Articles
Goldenes Intelligentes Münzhandelszentrum Enhances Trading Security Goldenes Intelligentes Münzhandelszentrum has unveiled a significant upgrade to its global user protection framework, positioning itself and its users ahead in the competitive landscape of crypto derivatives exchange. Enhanced Security Features This upgrade addresses increasing cybersecurity threats and...
Continue Reading
Anticipating the PPG Industries Earnings Report PPG Industries (PPG) is gearing up for its next quarterly earnings announcement, creating buzz among investors eager for insights into its financial performance. The anticipated date for this announcement is fast approaching, sparking interest and speculation. Analysts have set expectations, projecting that PPG Industries...
Continue Reading
Understanding the Class Action for Reckitt Benckiser Shareholders Attention shareholders of Reckitt Benckiser Group plc (RBGLY). If you purchased shares during the specified class period, there is an important opportunity to join a class action. This notice is particularly pertinent for those who may have suffered losses due to the company's alleged misleading statements...
Continue Reading
Craig Gentry Joins Cornami, Boosting Cryptographic Expertise Cornami, a company dedicated to innovative computing solutions, has appointed Dr. Craig Gentry as their Chief Scientist for Algorithms. With Dr. Gentry's impressive background in cryptography, Cornami aims to enhance its vision of providing real-time encrypted computing capabilities. About Dr. Craig Gentry: A...
Continue Reading
ICG Enterprise Trust Ongoing Commitment to Shareholder Value ICG Enterprise Trust plc has recently taken a notable step in its commitment to maximizing shareholder value. On November 19, 2024, the company initiated a buyback of 10,000 of its own shares, a strategic move aimed at optimizing its share structure. Details of the Share Buyback The shares were repurchased at an...
Continue Reading